# FY22 Results

25 August 2022



#### FY22 delivered strong growth with profit

Originations

\$732.8m

+52%

FY21: \$483.4m

**Closing Gross Loans** 

\$701.3m

+64%

FY21: \$427.1m

Realised Portfolio Yield<sup>1</sup>

34.1%

+1.4 ppts

FY21: 32.7%

**16K+** customers

**80**+

Revenue<sup>2</sup>

\$178.3m

+51%

FY21: \$117.7m

Operating Cash Flow<sup>3</sup>

\$58.8m

+78%

FY21: \$33.1m

EBITDA<sup>4</sup>

\$12.1m

+2274%

FY21: \$0.5m

<sup>1.</sup> All references to Realised portfolio yield in this document represent Revenue divided by Average Gross Loans, annualised.

<sup>2.</sup> All references to Revenue in this document represent Total income before transactions costs. All figures are expressed in AUD terms unless otherwise specified.

<sup>3.</sup> FY21 Operating Cash Flow was previously reported as \$34.8m, with the movement being due to a \$1.7m reclassification from Operating Cash Flow to Investing Cash Flow

<sup>4.</sup> All references to EBITDA in this document represent Earnings before interest on lease liabilities, tax, depreciation and amortisation, share-based payments, and FX Gain/Loss. FY21 EBITDA was previously reported as \$0.4m, with the \$0.1m increase arising from the exclusion of FX Gain/Loss from EBITDA.

#### **Expanded product suite to drive growth**

#### **Small Business Loan**

- **⊘** \$5K \$150K
- Term of 3 24 months

#### **Prospa Plus Business Loan**

- © \$150K \$500K
- Term of up to 36 months

#### **Line of Credit**

- **⊘** \$2K \$150K facility
- Use and reuse as often as customers require, during a 24 month renewable term
- © Customers only pay interest on the funds they use

AU

\$40.7K Average business loan amount<sup>1</sup>

**9.3%** Growth in average amount vs FY21

**\$44.1K** Average business loan amount<sup>1</sup>

**39.6%** Growth in average amount vs. FY21

**\$53.1K** Average facility limit

**15.3%** Growth in average facility limit vs FY21


Line of Credit was launched to New Zealand small business in July 2022

#### **Business Account (live)**

- Business transaction account
- Business Visa debit card

#### **Upcoming features:**

- Overdraft
- BillPay
- Invoicing



NZ

# Technology investment underpins our value proposition

#### **Delivered**

- Prospa Plus Business Loans across ANZ
- Line of Credit in New Zealand
- Core technology upgraded to deliver Line of Credit in NZ
- Business Account trial completed with existing customers
- Business Account, with visa debit card now available
- New mobile app provides single view of all credit products and Prospa's Business Account

#### Next



Core technology upgrades for further enhancements across all products and services

#### **Business Account**



Overdraft




BillPay



Invoicing



Marketing & channel engagement activity



# Well positioned as the leading online lender in a growing small business market

Despite uncertain market conditions, including rising inflation, tight labour market and supply chain challenges, small business continue to invest in their future

>97%

of AU businesses are small businesses in size and turnover

34%

increase in small business registrations in 2021 vs 2019 Prospa's significant growth in the small business credit space reflects a highly engaged customer base

81%

of AU small businesses are anticipating growth over the next 12 mths<sup>1</sup>

42%

of AU small businesses are forecasting revenue growth in the next 12 mths, at an average of 23%<sup>1</sup> 1 out of 4

business owners intend to borrow for their next phase of growth<sup>1</sup>







# Proven resilience to adapt to evolving market conditions

- The RBA announced the first target cash rate increases in more than a decade (May, June, July & August 2022), with rates anticipated to rise further throughout FY23
- Despite rising interest rates, small business credit demand remains strong
- ✓ No change to the Board mandated static loss rate of between 4-6%
- Continues to be a favourable environment for Prospa to capture a greater share of small businesses with good credit quality in what is a highly fragmented market

#### Focus areas



Margin protection



Target loss rate



Funding efficiencies





Cost management





# Diversified and flexible portfolio to mitigate risks and target growth sectors

- Prospa's proprietary Credit Decision Engine enables real-time dynamic risk profiling
- Specifically target sectors and geographies based on changing market conditions and customer needs
- >50% of originations are repeat and return customers











**SECTION 2** 

# Financial update



#### Summary financials<sup>1</sup>

	\$m	FY22	FY21	Var. on pcp	Var. % on pcp
1	Closing gross loans	701.3	427.1	274.2	64.2%
2	Total revenue	178.3	117.7	60.6	51.4%
3	Transaction costs	(11.4)	(7.3)	(4.2)	57.2%
4	Funding costs	(23.3)	(17.9)	(5.4)	30.4%
	Gross profit <sup>2</sup>	143.6	92.6	51.0	55.0%
5	Loan impairment	(47.3)	(27.3)	(20.0)	73.4%
6	Employee expenses	(48.2)	(35.2)	(12.9)	36.7%
7	Operating expenses	(36.0)	(29.6)	(6.4)	21.7%
	Total expenses	(131.4)	(92.1)	(39.4)	42.7%
	EBITDA	12.1	0.5	11.6	2274.0%
8	Unrestricted cash	49.9	39.8	10.1	25.5%
	Operating cash flow	58.8	33.1	25.7	77.7%

- 1 Closing gross loans of \$701.3m in FY22, an all time high for Prospa and representing a 64.2% increase on FY21, demonstrating strong demand for credit by small businesses
- Revenue increase of 51.4%, to \$178.3m, supported by existing product growth
- 3 Transaction costs increased in line with loan book and revenue growth
- 4 Cost of funds has increased at a lower rate than revenue and the loan book due to lower funding costs from more efficient funding facilities and the term ABS issued in Sept (5.0% vs 5.9%), despite central bank interest rate increases
- 5 Please refer to page 12 for a breakdown of the impairment expense
- Employee expenses grew 36.7%, mainly from investment in technology and product to execute the new product strategy, noting that FY21 included \$2.7m of Jobkeeper benefit. Excluding the benefit, the increase was 27.2%
- Increase of 21.7% in operating expenses due to growth in sales and marketing expenses to support origination growth, and scaling of technology
- Unrestricted cash increased by 25.5%, driven by a 77.7% increase in operating cash flow, showing strong cash generation, an inherent feature of Prospa's business model

prospa

<sup>1.</sup> Totals may not add up precisely due to rounding.


<sup>2.</sup> All references to Gross Profit in this document are calculated as Total income less Funding Costs less Transaction Costs


### High quality loan book growth supported by strong funding facilities

#### prospa

10









- Closing gross loans of \$701.3m, a significant increase of 64.2% on pcp
- Book growth supported by a longer average term of ~20 months
- NZ closing gross loans are AUD \$114.6m vs \$65.7m in FY21


- \$702.0m of available third-party facilities as at 30 June 2022 (FY21: \$458.6m)
- On 1 July 2022, the Propela Trust's facility limit
  was expanded from \$67.5m to \$135m to support
  future book growth in Australia, increasing the
  undrawn capacity to \$126.6m
- Three main Australian warehouses have a revolving period, which ends in May 2024, Sep 2024, and Mar 2025. Two NZ warehouses have a revolving period ending Aug 2024 and Sep 2024
- Prospa has no corporate debt

- Overall Credit provisioning of 7.2% for FY22, down from 7.9% in FY21
- Focus remains on maintaining the credit quality of the loan book
- Static loss rates remain within the Board mandated 4-6% range

### Continued strong margins with higher yield and lower cost of funds well placed for future interest rate rises







- Originations of \$732.8m, a strong increase of 52% on pcp
- Further margin improvement also achieved in FY22
- Demand from small business continues with June 2022 recording the highest ever month of originations at \$104.6m. July was also a strong month at \$66m in a traditionally slow period (July 21: \$41.8m)
- Optimised funding cost improvements with a 0.9 percentage point reduction, reflecting improved margins in existing facilities and the impact of the inaugural \$200m term ABS issued in Sep 2021
- The improved margins will partially offset some base rate increases


- Strong yield management has been a focus for the business with 34.1% portfolio yield achieved in FY22, up 1.4 percentage points from FY21
- Maintained an attractive Net Interest Margin (NIM) of 29.6% in a rising rate environment, with both yield increasing and cost of funds reducing

Gross Profit Margin is equal to Gross Profit / Total Revenue

<sup>2.</sup> Funding cost rate is equal to Funding Costs / Average Funding Debt.

NIM is equal to (Total Revenue – Funding Costs) / Average Gross Loans.


#### Significant reduction in net bad debt expense




- √ \$21.8m of the impairment expense increase in FY22 was as result of loan book growth, not increased risk
- Despite the significant loan book growth, the net bad debt expense was lower (FY22 \$30.1m vs FY21 \$35.1m), demonstrating the effectiveness of Prospa's risk management capability

AGL – Average Gross Loans


## Revenue to operating cash conversion enabling self-funded future growth





- Revenue growth of 51% has converted to a 78% increase in operating cash flow, generating \$58.8m in FY22
- Strong operating cash supported increased technology investment, loan book growth and increased cash at bank
- Cash generation expected to continue, even with increased investments in product and development
- Well positioned to capitalise on future growth opportunities


## Cost management demonstrating scale and operating leverage potential





- General and Administration (G&A) cost has showed a modest increase with only a 3.1% increase from FY21, demonstrating the scale potential of the business as we grow further
- Sales and Marketing (S&M) cost increased 31.6%, while originations grew by 52%, representing operating leverage of 1.6x in sales and marketing
- Product and Product Development (P&D) cost increased 45.0% in the year, largely to support future growth through the scaling of existing products, as well as developing new products such as the Line of Credit launch in NZ and recently launched Business Account

#### Untapped potential in shareholder value



Record breaking FY22 results, with the Company experiencing sustained growth. The share price is yet to reflect business performance.



**SECTION 3** 

# Strategy and outlook



Our growth strategy is to leverage our products to expand reach and drive efficiencies

#### In FY23<sup>1</sup>:

- Prospa expects strong demand for credit from small business owners across all key industries in Australia and New Zealand
- Increase customer acquisition

 Existing products will scale within the Australian and New Zealand addressable market

Additional revenue growth from a larger base of customers

Yield to remain relatively stable and credit risk outcomes to remain within the Board target <sup>2</sup>

Further operating leverage from increased scale

 Commitment to continue our investment in technology to introduce new products and enhance Prospa's value proposition

Increase life-time value with more engaging products



The uncertain economic environment may change some of these expectations including a deterioration in demand or credit performance.

<sup>2.</sup> The Board mandated static loss rate target is 4-6% over the life of cohorts.





**SECTION 4** 

# Additional Information

#### **Profit and Loss**

Profit and Loss (\$m) <sup>1</sup>	FY22	FY21
Interest income before transaction costs	163.2	108.5
Other income	15.1	9.3
Total income	178.3	117.7
Transaction costs	(11.4)	(7.3)
Funding costs	(23.3)	(17.9)
Gross profit	143.6	92.6
Loan impairment expense	(47.3)	(27.3)
Employee expenses	(48.2)	(35.2)
Operating expenses	(35.9)	(29.7)
Total expenses	(131.4)	(92.1)
EBITDA	12.1	0.5
Depreciation	(2.6)	(2.7)
Amortisation	(4.7)	(5.4)
Interest on lease liabilities	(0.3)	(0.5)
Share based payments	(3.0)	(4.8)
PBT	1.7	(13.0)
Tax expense	5.1	3.5
NPAT	6.7	(9.5)
		J

1. Totals may not add up precisely due to rounding.

#### **Statutory Balance Sheet**

Statutory Balance Sheet (\$m) <sup>1</sup>	Jun-22	Jun-21
Cash and cash equivalents	105.8	80.4
Bank deposits	-	1.1
Loan receivables	650.5	393.4
Other financial assets	0.6	-
Derivative financial assets	7.5	0.0
Prepayments and other assets	3.2	2.5
Property, plant and equipment	0.3	0.7
Right-of-use assets	7.9	5.0
Intangible assets	17.9	7.2
Deferred tax assets	18.3	14.3
Total assets	812.1	504.5
Trade and other payables	12.8	7.8
Current tax liabilities	1.5	-
Employee benefits	8.0	5.6
Lease liabilities	9.5	6.7
Borrowings	640.8	359.9
Total liabilities	672.7	380.0
Net assets	139.4	124.5
Issued Capital	611.8	610.9
Reserves	(415.2)	(422.5)
Accumulated losses	(57.2)	(63.9)
Total equity	139.4	124.5

1. Totals may not add up precisely due to rounding.

#### **Statutory Cash Flow**

Statutory Cash Flow (\$m) <sup>1</sup>	FY22	FY21
Cash flows from operating activities		
Finance income received	161.3	107.5
Other income received	11.7	10.0
Interest and other finance costs paid	(24.2)	(17.9)
Payments to suppliers and employees	(90.0)	(71.1)
Income tax refunded	-	0.7
JobKeeper payments received	-	3.9
Net cash from operating activities	58.8	33.1
Cash flows from investing activities		
Net increase in loans advanced to customers	(297.9)	(89.0)
Payments for other financial assets	(0.6)	(55.5)
Payments for intangibles	(15.4)	(4.8)
Decrease in bank deposits	1.1	-
Net cash used in investing activities	(312.9)	(93.8)
Cash flows from financing activities		
Proceeds from borrowings	389.1	136.9
Repayment of borrowings	(107.6)	(104.4)
Repayment of finance leases	(2.3)	(2.0)
Payments for share repurchase	(0.4)	(0.0)
Proceeds from exercise of options	0.0	0.2
Proceeds from sale of loan shares	1.3	0.0
Cash settled employee rights	(0.0)	-
Net cash from financing activities	280.1	30.8
Net increase / (decrease) in cash and cash equivalents	26.1	(30.0)
Total Cash at the beginning of the financial period	80.4	110.3
Foreign Exchange Effect	(0.7)	-
Total Cash at the end of the financial period	105.8	80.4

<sup>1.</sup> Totals may not add up precisely due to rounding.

#### **Key Metrics**

	FY22	FY21
Loan book		
Originations (\$m)	732.8	483.4
Gross Originations (\$m)1	973.9	608.4
Closing Gross Loans (\$m)	701.3	427.1
Average Gross Loans (\$m)	523.4	360.0
Realised Portfolio Yield (%)	34.1%	32.7%
Premium Risk Grades (%)	45.4%	42.0%
NIM as a % of Average Gross Loans	29.6%	27.7%
Funding		
Funding Cost Rate (%)	5.0%	5.9%
Average Funding Debt (\$m)	467.4	305.3
Productivity metrics		
CAPEX as a % of Revenue	8.6%	4.1%
Employee and Operating Expenses as a % of Revenue <sup>2</sup>	47.1%	55.2%
Composition of loan impairment		
Impairment Expense: Net Bad Debt Expense (\$m)	30.1	35.1
Impairment Expense: Provision Movement (\$m)	17.1	(7.7)
Provision Rate (%)	7.2%	7.9%
Net Bad Debt Expense as a % of Average Gross Loans	5.7%	9.7%

<sup>1.</sup> Originations including carryover from refinances.

<sup>2.</sup> Excludes JobKeeper payments.

#### **Important Notice and Disclaimer**

The material in this presentation has been prepared by Prospa Group Limited (PGL) and is general background information about Prospa's (PGL and its subsidiaries) activities and is current at the date of the presentation, 25 August 2022.

This presentation may contain statements that are, or may be deemed to be, forward looking statements. Such statements can generally be identified by the use of words such as "believe", "estimate", "plan", "target", "project", "anticipate", "expect", "intend", "likely", "may", "will", "could" or "should" and similar expressions. Indications of strategy, plans, objectives, targets, goals, future events or intentions are also forward looking statements.

You should not place undue reliance on such forward-looking statements. Such forward looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors, many of which are beyond the control of PGL or any of its related entities which may cause actual results to differ materially from those expressed or implied in such statements.

No representation or warranty, express or implied, is made as to the accuracy, reliability, adequacy or completeness of the information contained in this presentation.

Past performance information in this presentation is given for illustrative purposes only and should not be relied upon as (and is not) an indication of future performance.

The information in the presentation is given for informational purposes only, is in summary form and does not purport to be complete. It is intended to be read by a professional analyst audience in conjunction with PGL's other announcements to ASX. It is not intended to be relied upon as advice to current shareholders, investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular shareholder or investor. No representation is made as to the accuracy, completeness or reliability of the presentation.

The views expressed in this presentation may contain information that has been derived from publicly available sources that have not been independent verified. No representation or warranty, express or implied, is made as to the accuracy, reliability, adequacy or completeness of the information. Market share information is based on management estimates except where explicitly identified.

To the maximum extent permitted by law, PGL and any person involved in the preparation of this presentation disclaim all liability and responsibility (including without limitation, any liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use or reliance on anything contained in, or omitted from, this presentation.

PGL is not obliged to, and does not represent that it will, update the presentation for future developments. All currency figures are in Australian dollars unless otherwise stated. Totals may not add up precisely due to rounding.